Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
WALTHAM, Mass., April 26, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in a fireside chat at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 2:50 p.m. ET.
A live audio webcast will be accessible through the Investors section of the company’s website at www.amagpharma.com, and will be archived for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
